Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic HCV Infection Clear all
Completed Phase 3 Interventional Results available

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C, Treatment Naive
Interventions
Ribavirin, Telaprevir, Pegylated interferon alfa-2a
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Results available

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI201335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

NCT02304159
View directory record Official record
Conditions
Hepatitis C, Cirrhosis
Interventions
daclatasvir, Sofosbuvir, Sovaldi, Ribavirin
Drug
Lead sponsor
Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
San Diego, California • Ventura, California • Bradenton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 4 Interventional

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

NCT00001854
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC

NCT00926120
View directory record Official record
Conditions
Hepatitis C
Interventions
Mogroside sweetener (PureLo)
Dietary Supplement
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

NCT00377182
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

NCT02114177
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

NCT03627299
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
300mg glecaprevir/pibrentasivir 120mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607800
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 22, 2026, 5:50 AM EDT
Active, not recruiting Phase 3 Interventional

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

NCT06868264
View directory record Official record
Conditions
HEPATITIS C VIRUS CHRONIC INFECTION
Interventions
Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
96
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

NCT00537407
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Debio 025, Peg-IFNα2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C

NCT02823457
View directory record Official record
Conditions
Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders
Interventions
VBMI
Behavioral
Lead sponsor
G.V. (Sonny) Montgomery VA Medical Center
Federal
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

NCT01215643
View directory record Official record
Conditions
Hepatitis C, Chronic Pain
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Ventura, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

Hepatitis C Antiviral Resistance in African-Americans

NCT00038974
View directory record Official record
Conditions
Hepatitis C
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

NCT00971308
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-824393
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Anaheim, California • Cypress, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jul 22, 2026, 5:50 AM EDT
Not listed Phase 2 Interventional

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

NCT00225537
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
4-Methylumbelliferone (Heparvit®)
Drug
Lead sponsor
MTmedical Institute of Health
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

Combination Drug Therapy for Patients With Hepatitis C

NCT00001729
View directory record Official record
Conditions
Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients

NCT00596960
View directory record Official record
Conditions
Alcohol Dependence, Chronic Hepatitis C
Interventions
Motivational Enhancement Therapy (MET), Health education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2014 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

NCT00087633
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], Copegus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 22, 2026, 5:50 AM EDT
Terminated Not applicable Interventional

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

NCT00655226
View directory record Official record
Conditions
Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression, HIV Infections
Interventions
Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2011 · Synced Jul 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

NCT00097435
View directory record Official record
Conditions
Hepatitis C
Interventions
Albuferon, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jul 22, 2026, 5:50 AM EDT